摘要
目的:通过Meta分析评价苏黄止咳胶囊联合阿斯美治疗感染后咳嗽的疗效及安全性。方法:利用万方数据库、PubMed数据库和中国知网,检索有关苏黄止咳胶囊联合阿斯美对感染后咳嗽治疗疗效的临床随机对照试验。对符合纳入标准的研究进行评价,使用Review Manager 5.4软件进行荟萃分析。结果:最终有6项临床随机对照试验符合纳入标准,总计627例患者。苏黄止咳胶囊联合阿斯美组(试验组)的总有效率高于对照组[RR=0.12,95%CI(0.06,0.24),P<0.00001],差异有统计学意义;试验组咳嗽症状评分低于对照组[MD=-0.61,95%CI(-0.73,-0.50)P<0.00001],差异有统计学意义;另外与对照组相比,试验组并未增加治疗后不良反应的发生,其中试验组与对照组恶心的不良反应发生率比较,无明显的统计学差异[RR=1.36,95%CI(0.55,3.37),P=0.50];试验组与对照组心慌/心悸的不良反应发生率比较,无明显的统计学差异[RR=0.63,95%CI(0.16,2.44),P=0.50];试验组与对照组胃部不适不良反应发生率比较,无明显的统计学差异[RR=1.19,95%CI(0.38,3.75),P=0.77];试验组与对照组嗜睡的不良反应发生率比较,无明显的统计学差异[RR=0.79,95%CI(0.21,3.02),P=0.73]。结论:苏黄止咳胶囊联合阿斯美治疗感染后咳嗽有较好的临床应用疗效,较低的不良反应发生率。
Objective:To evaluate the efficacy and safety of Suhuangzhike capsule combined with Asmeton in the treatment of post-infection cough through Meta-analysis.Methods:The clinical randomized controlled trials of Suhuangzhike capsule combined with Asmeton in the treatment of post-infection cough were searched by using Wanfang database,PubMed database and CNKI.The studies that met the inclusion criteria were evaluated and meta-analysis was performed using Review Manager 5.4 software.Results:Finally,six clinical randomized controlled trials met the inclusion criteria were selected,with a total of 627 patients.The effective rate of Suhuangzhike capsule combined with Asmeton group(experimental group)was higher than that of the control group[RR=0.12,95%CI(0.06,0.24),P<0.00001],with statistical significance.The cough symptom score of the experimental group was lower than the control group[MD=-0.61,95%CI(-0.73,-0.50)P<0.00001],and there was a statistical difference.In addition,compared with the control group,the experimental group did not increase the incidence of adverse reactions after treatment.There was no significant difference in the incidence of nausea between the experimental group and the control group[RR=1.36,95%CI(0.55,3.37),P=0.50].There was no significant difference in the incidence of adverse reactions of heart palpitations between the experimental group and the control group[RR=0.63,95%CI(0.16,2.44),P=0.50].There was no significant difference in the incidence of adverse reactions of stomach discomfort between the experimental group and the control group[RR=1.19,95%CI(0.38,3.75),P=0.77].There was no significant difference in the incidence of adverse reactions of drowsiness between the experimental group and the control group[RR=0.79,95%CI(0.21,3.02),P=0.73].Conclusion:Suhuangzhike capsule combined with Asmeton has better clinical efficacy and lower incidence of adverse reactions in the treatment of post-infectious cough.
作者
李阳
王登本
魏永梅
马俊彦
高颖
刘美芳
李建英
张惠民
鱼军
LI Yang;WANG Deng-ben;WEI Yong-mei;MA Jun-yan;GAO Ying;LIU Mei-fang;LI Jian-ying;ZHANG Hui-min;YU Jun(Xi'an Central Hospital of Shaanxi Province,Xi'an710003;The Medicine Academy of Yan'an University,Yan'an716000)
出处
《实用中西医结合临床》
2021年第20期1-5,共5页
Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine
基金
陕西省西安市科技计划项目(编号:2019115713YX012SF045)
陕西省重点研发计划项目(编号:2019SF-020)
陕西省重点研发计划项目(编号:2019SF-175)。
